CSIMarket
 
Quince Therapeutics Inc   (NASDAQ: QNCX)
Other Ticker:  
 
 
Price: $1.3000 $-0.06 -4.412%
Day's High: $1.43 Week Perf: 8.33 %
Day's Low: $ 1.30 30 Day Perf: 52.94 %
Volume (M): 376 52 Wk High: $ 2.45
Volume (M$): $ 489 52 Wk Avg: $1.28
Open: $1.41 52 Wk Low: $0.56



 Market Capitalization (Millions $) 57
 Shares Outstanding (Millions) 44
 Employees 36
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Quince Therapeutics Inc


   Company Address: 611 Gateway Boulevard, South San Francisco 94080 CA
   Company Phone Number: 910-5717   Stock Exchange / Ticker: NASDAQ QNCX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -2%    
BCRX   -2.6%    
BIIB   -2.76%    
EXEL   -2.93%    
GILD   -1.35%    
MRNA   -2.89%    
• View Complete Report
   



Business Update

Innovation Amidst Volatility Quince Therapeutics Advances in Rare Disease Treatments and Fiscal Resilience in 2024,

Published Tue, Mar 25 2025 4:12 AM UTC

Unlocking Potential: Quince Therapeutics Fiscal Year 2024 Financial Results and Strategic Developments in Rare Disease Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a pioneering biotechnology enterprise headquartered in South San Francisco, is steadfastly advancing the therapeutic landscape for rare diseases by leveraging the intrinsic potential of patient biology....

Business Update

Quince Therapeutics Showcases Progress in Ataxia-Telangiectasia Treatment Safety Data and Fast Track Designation Hi...

Published Tue, Nov 12 2024 3:36 AM UTC

In a significant advancement for the field of pediatric neurology and rare disease therapeutics, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology firm based in South San Francisco, has presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; NCT02770807) clinical trial at the 53rd Child Neurology Society (CNS) Ann...

Business Update

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDe...

Published Thu, Aug 15 2024 12:09 PM UTC

Quince Therapeutics Unveils Promising Data on EryDex Treatment for Ataxia-Telangiectasia and Reports Encouraging Financial Outlook In the realm of biotechnology, the quest for effective treatments for rare diseases remains one of the most formidable challenges. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage company at the forefront of this endeavor, has recently ma...

Business Update

FDA Grants Fast Track Designation to Quince Therapeutics for EryDex System Targeting Ataxia-Telangiectasia ...

Published Mon, Jun 3 2024 11:38 AM UTC

South San Francisco, Calif. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its innovative EryDex System. This decision aims to expedite the development and review of the EryDex System, specifically targeting patients suffering from Ataxia-Telangiectasia...

Business Update

Quince Therapeutics: Pioneering Patient-Driven Drug Delivery and Looking Beyond Q1 Financial Results

Published Mon, May 13 2024 1:47 PM UTC

Quince Therapeutics, a distinguished player in the biotechnology industry, is persistently pushing the boundaries of innovation with its unique patient-driven drug delivery technology. Its unwavering dedication to revolutionizing the delivery of rare disease therapeutics is the company s unique selling point that sets it apart from its competitors. With the close of the firs...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com